Welcome to our dedicated page for Neuphoria Therapeutics SEC filings (Ticker: NEUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 250-page biotech filing can feel like decoding lab notes. Neuphoria Therapeutics’ SEC documents dive deep into clinical-trial data, cash runway projections, and dilution risks that matter to every biotech investor. If you have ever asked, “Where can I find Neuphoria Therapeutics’ quarterly earnings report 10-Q filing?” or searched for “Neuphoria Therapeutics insider trading Form 4 transactions,” you already know how scattered EDGAR can be.
Stock Titan solves that problem. Our AI reads each 10-K, 10-Q, and 8-K the moment it hits EDGAR, then delivers plain-English summaries so you can focus on BNC210 trial timelines, partnership milestones, or financing covenants without wading through dense pharmacology. Need Form 4 alerts? We stream Neuphoria Therapeutics Form 4 insider transactions real-time and flag patterns in executive stock transactions Form 4 filings. Want context? Our platform links every footnote to an explanation, turning “understanding Neuphoria Therapeutics SEC documents with AI” from wishful thinking into a two-minute read.
Whether you’re gauging dilution risk through an annual report 10-K simplified, looking for proxy statement executive compensation details, or checking a sudden 8-K material events explained, you’ll find it here. Investors routinely use our earnings report filing analysis to spot R&D expense trends, compare burn rate quarter-over-quarter, and monitor compliance triggers before they affect valuation. All filings, all the time—kept current with real-time updates and backed by expert narrative so Neuphoria Therapeutics SEC filings are explained simply.
NeuroBo Pharmaceuticals (NEUP) amended its prospectus supplement to update its at-the-market program, allowing sales of up to $15,478,160 of common stock from time to time through H.C. Wainwright & Co. as sales agent under a previously executed Sales Agreement. Sales may be made in transactions deemed an at-the-market offering under Rule 415(a)(4).
The update reflects eligibility under General Instruction I.B.6 of Form S-3, which limits primary sales to no more than one-third of public float in any 12-month period while public float is below $75 million. Public float was $46,434,480, based on 2,321,724 non-affiliate shares at $20.00 as of October 6, 2025. In the past 12 months, the company sold $5,352,879 under I.B.6. Wainwright earns a 3.0% commission on gross proceeds.
Neuphoria Therapeutics (NEUP) reported topline results from its AFFIRM-1 Phase 3 trial of BNC210 in social anxiety disorder, stating the study did not meet its primary endpoint on the SUDS score during the public speaking performance phase. Analyses of secondary endpoints also did not show statistically significant differences versus placebo.
The company noted BNC210’s safety and tolerability remained favorable and consistent with prior studies. Neuphoria highlighted its partnership with Merck, under which Merck is running a Phase 2 trial of MK-1167 in Alzheimer’s disease and is responsible for all costs; the collaboration includes eligibility for up to
As of June 30, 2025, cash and cash equivalents were
Neuphoria Therapeutics (NEUP) is advancing BNC210, an oral selective negative allosteric modulator of the α7 receptor, across acute social anxiety disorder (SAD) and chronic PTSD programs while maintaining a broader CNS pipeline and partnerships. The Phase 2b ATTUNE PTSD trial met its primary endpoint (CAPS-5 change; p=0.048) with additional statistically significant benefits on depressive symptoms and sleep. PREVAIL narrowly missed its primary public-speaking SUDS endpoint but showed encouraging phase-specific and secondary trends.
The company initiated screening for Phase 3 AFFIRM-1 in SAD targeting ≈332 adults with topline results expected early Q4 2025, and plans a Phase 2b/3 PTSD study contingent on capital. Neuphoria holds multiple patent families with potential protection through 2040, collaborative arrangements including Merck and Carina, and faces typical biotech risks including need for additional capital, regulatory approvals, manufacturing scale-up, and safety monitoring for liver function.
Neuphoria Therapeutics insider filing: Spyros Papapetropoulos, President, CEO and director of Neuphoria Therapeutics (NEUP), reported an option grant on 08/27/2025 for 34,559 employee stock options with an exercise price of $8.27 per share. The options vest monthly over four years beginning August 1, 2025, at a rate of 2.0833% of the shares on the last day of each month, and expire on 08/27/2035. After the grant, the reporting person beneficially owns 74,088 shares of common stock directly. The Form 4 was signed on 09/01/2025.
FAQ
What is the current stock price of Neuphoria Therapeutics (NEUP)?
What is the market cap of Neuphoria Therapeutics (NEUP)?
